Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Shape Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Shape Therapeutics

Shape Therapeutics

Series B

ShapeTX, a biotech firm, pioneers in AI-driven RNA therapies for genetic diseases, including Alzheimer's and Parkinson's.

HQ
Seattle, WA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Shape Therapeutics (ShapeTX) was founded with the mission to pioneer the field of programmable RNA medicines aimed at repairing genetic causes of diseases. The company's vision is to leverage innovations in artificial intelligence (AI) and RNA technology to develop groundbreaking RNA editing therapies, next-generation adeno-associated viruses (AAVs), and advanced gene therapy manufacturing processes. ShapeTX focuses on creating treatments for a wide range of diseases, including rare genetic disorders and debilitating conditions such as Alzheimer's and Parkinson's.

Notable affiliates and investors in ShapeTX include leading figures in biotechnology and AI, although specific names are not provided. The company has achieved significant milestones by integrating AI to analyze extensive datasets, enabling intelligent decision-making in therapeutic development. ShapeTX's impact is evident in its ability to offer pharmaceutical innovators tools to design effective treatments, positioning the company as a leader in the biotech industry focused on RNA-targeted therapies.

Shape Therapeutics - Products & Services

  • RNA Editing Platform logo

    RNA Editing Platform

    A programmable RNA editing platform developing therapies for genetic disease.

    Competing Products

    Artan Bio logo

Shape Therapeutics - Similar Companies

Artan Bio logo

Artan Bio

artan.bio

Airna logo

Airna

airna.com

Inceptive logo

Inceptive

inceptive.life

Alltrna logo

Alltrna

alltrna.com

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

ReCode Therapeutics logo

ReCode Therapeutics

ReNAgade Therapeutics logo

ReNAgade Therapeutics

Mana.bio logo

Mana.bio

mana.bio

Atalanta Therapeutics logo

Atalanta Therapeutics

atalantatx.com

Laronde logo

Laronde

laronde.bio

Silence Therapeutics logo

Silence Therapeutics

Orbital Therapeutics logo

Orbital Therapeutics

Remix Therapeutics logo

Remix Therapeutics

Atomic AI logo

Atomic AI

atomic.ai

Alnylam Pharmaceuticals aln logo

Alnylam Pharmaceuticals aln

alnylam.com

Shape Therapeutics - Quick Facts

Who are Shape Therapeutics' competitors?

Companies similar to Shape Therapeutics include Artan Bio, Airna, Inceptive and Alltrna.

When was Shape Therapeutics founded?

Shape Therapeutics was founded in 2018.

Where is Shape Therapeutics' headquarters located?

Shape Therapeutics' headquarters is located in Seattle, WA, US.

When was Shape Therapeutics' last funding round?

Shape Therapeutics' most recent funding round was for $112M (USD) in July 2021.

How much has Shape Therapeutics raised to-date?

As of Jul 15, 2021, Shape Therapeutics has raised a total of $147.5M (USD).

How many employees does Shape Therapeutics have?

Shape Therapeutics has 149 employees as of Feb 4, 2024.

Shape Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research